Federated Hermes Inc. Buys 418 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Federated Hermes Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,214 shares of the biopharmaceutical company’s stock after acquiring an additional 418 shares during the period. Federated Hermes Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,823,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in REGN. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Regeneron Pharmaceuticals by 129.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after acquiring an additional 122,103 shares in the last quarter. TD Asset Management Inc increased its position in shares of Regeneron Pharmaceuticals by 64.4% during the third quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock worth $148,353,000 after acquiring an additional 70,628 shares in the last quarter. Finally, Fred Alger Management LLC grew its position in Regeneron Pharmaceuticals by 74,804.8% in the third quarter. Fred Alger Management LLC now owns 62,920 shares of the biopharmaceutical company’s stock valued at $51,781,000 after purchasing an additional 62,836 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 20th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, UBS Group raised their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $883.20 on Friday. The firm has a 50-day moving average of $948.00 and a 200-day moving average of $894.04. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market cap of $96.94 billion, a PE ratio of 25.42, a P/E/G ratio of 2.56 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the company posted $10.96 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.